TLR2 on CD4+ and CD8+ T cells promotes control of Mycobacterium tuberculosis infection
European Journal of Immunology · 2024
DOI: 10.1002/eji.202350715 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2024. Verfasst von Scott M Reba und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Case Western Reserve University & University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Toll-Like Receptor 2, CD8-Positive T-Lymphocytes, CD4-Positive T-Lymphocytes, Mycobacterium tuberculosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Although a role for TLR2 on T cells has been indicated in prior studies, in vivo stimulation of TLR2 on T cells by Mtb and its impact on Mtb infection has not been tested. Furthermore, it is not known if the enhanced susceptibility to Mtb of Tlr2 gene knockout mice is due to its role in macrophages, T cells, or both. To address TLR2 on T cells, we generated Tlr2 fl/fl xCd4 cre/cre mice, which lack expression of TLR2 on both CD4 and CD8 T cells, to study the in vivo role of TLR2 on T cells after aerosol infection with virulent Mtb . Deletion of TLR2 in CD4+ and CD8+ T cells reduces their ability to be co‐stimulated by TLR2 ligands for cytokine production. These include both pro‐ (IFN‐γ, TNF‐α) and anti‐inflammatory cytokines (IL‐10). Deletion of TLR2 in T cells affected control of Mtb in the lungs and spleens of infected mice. This suggests that T‐cell co‐stimulation by mycobacterial TLR2 ligands in vivo contributes to the control of Mtb infection in the lung and spleen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Case Western Reserve University & University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
- Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
- Janssen Biopharma Inc., Brisbane, California, USA.
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Reba, S. M., Li, Q., Onwuzulike, S., Nagy, N., Fletcher, S., Parker, K., Shaw, R. J., Umphred-Wilson, K., Shukla, S., Harding, C. V., Boom, W. H., & Rojas, R. E. (2024). TLR2 on CD4+ and CD8+ T cells promotes control of Mycobacterium tuberculosis infection. European Journal of Immunology. https://doi.org/10.1002/eji.202350715
Vancouver
Reba SM, Li Q, Onwuzulike S, Nagy N, Fletcher S, Parker K, et al. TLR2 on CD4+ and CD8+ T cells promotes control of Mycobacterium tuberculosis infection. European Journal of Immunology. 2024. doi:10.1002/eji.202350715
BibTeX
@article{Reba2024,
author = {Reba, Scott M and Li, Qing and Onwuzulike, Sophia and Nagy, Nancy and Fletcher, Shane and Parker, Kyle and Shaw, Rachel J and Umphred-Wilson, Katharine and Shukla, Supriya and Harding, Clifford V and Boom, W Henry and Rojas, Roxana E},
title = {TLR2 on CD4+ and CD8+ T cells promotes control of Mycobacterium tuberculosis infection},
journal = {European Journal of Immunology},
year = {2024},
doi = {10.1002/eji.202350715}
}
EUVIMED